Search Result

Results for "

inhibits platelet aggregation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Platelet-activating Factor Receptor (PAFR) (7) 5-HT Receptor (4) Adenosine Receptor (3) Adenylate Cyclase (1) Adrenergic Receptor (1) AMPK (1) Apoptosis (14) Autophagy (1) Bacterial (2) Biochemical Assay Reagents (2) Calcium Channel (1) Caspase (1) Cathepsin (1) COX (5) Cytochrome P450 (3) DNA/RNA Synthesis (1) Drug Metabolite (2) DYRK (1) Endogenous Metabolite (16) Estrogen Receptor/ERR (1) Fungal (2) Glycoprotein VI (2) Histamine Receptor (1) HIV (1) Influenza Virus (3) Integrin (9) Interleukin Related (1) Isotope-Labeled Compounds (9) JAK (1) JNK (1) Lipoxygenase (2) LPL Receptor (1) Monoamine Oxidase (1) NF-κB (4) NO Synthase (3) P2Y Receptor (23) p38 MAPK (1) Parasite (3) PGE synthase (2) Phosphodiesterase (PDE) (6) Potassium Channel (1) Prostaglandin Receptor (15) Protease Activated Receptor (PAR) (11) SARS-CoV (2) Src (1) STAT (1) Syk (1) TAM Receptor (1) Thrombin (7) TNF Receptor (1) Toll-like Receptor (TLR) (1) Tyrosinase (1) VSV (1)
By Research Areas:	Cancer (27) Cardiovascular Disease (121) Endocrinology (7) Infection (9) Inflammation/Immunology (24) Metabolic Disease (13) Neurological Disease (10)

By Targets:

Platelet-activating Factor Receptor (PAFR) (7)

5-HT Receptor (4)

Adenosine Receptor (3)

Adenylate Cyclase (1)

Adrenergic Receptor (1)

AMPK (1)

Apoptosis (14)

Autophagy (1)

Bacterial (2)

Biochemical Assay Reagents (2)

Calcium Channel (1)

Caspase (1)

Cathepsin (1)

COX (5)

Cytochrome P450 (3)

DNA/RNA Synthesis (1)

Drug Metabolite (2)

DYRK (1)

Endogenous Metabolite (16)

Estrogen Receptor/ERR (1)

Fungal (2)

Glycoprotein VI (2)

Histamine Receptor (1)

HIV (1)

Influenza Virus (3)

Integrin (9)

Interleukin Related (1)

Isotope-Labeled Compounds (9)

JAK (1)

JNK (1)

Lipoxygenase (2)

LPL Receptor (1)

Monoamine Oxidase (1)

NF-κB (4)

NO Synthase (3)

P2Y Receptor (23)

p38 MAPK (1)

Parasite (3)

PGE synthase (2)

Phosphodiesterase (PDE) (6)

Potassium Channel (1)

Prostaglandin Receptor (15)

Protease Activated Receptor (PAR) (11)

SARS-CoV (2)

Src (1)

STAT (1)

Syk (1)

TAM Receptor (1)

Thrombin (7)

TNF Receptor (1)

Toll-like Receptor (TLR) (1)

Tyrosinase (1)

VSV (1)

By Research Areas:

Cancer (27)

Cardiovascular Disease (121)

Endocrinology (7)

Infection (9)

Inflammation/Immunology (24)

Metabolic Disease (13)

Neurological Disease (10)

180

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

5(S)15(S)-DiHETE	Interleukin Related	Cardiovascular Disease Inflammation/Immunology
5(S)15(S)-DiHETE is an “activated” intermediate, inhibits platelet aggregation with an IC₅₀ of 1.3 μM. 5(S)15(S)-DiHETE enhances the rate of either LXA4 or LXB4 biosynthesis .

Cloricromen hydrochloride Cloricromene hydrochloride	Others	Cardiovascular Disease
Cloricromen (Cloricromene) hydrochloride is a **platelet aggregation** inhibitor. Cloricromen hydrochloride can inhibit platelet aggregation in man and in experimental thrombosis .

Cloricromen Cloricromene; AD6	Biochemical Assay Reagents	Cardiovascular Disease
Cloricromen (Cloricromene) is a **platelet aggregation** inhibitor. Cloricromen can inhibit platelet aggregation in man and in experimental thrombosis .

Ifenprodil glucuronide	Others	Cardiovascular Disease
Ifenprodil glucuronide is a derivative of Ifenprodil. Ifenprodil is a vasodilator and an inhibitor of platelet aggregation, and Ifenprodil glucuronide has no effect on platelet aggregation and arterial contraction .

Orbofiban	Integrin	Cardiovascular Disease
Orbofiban is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.

Orbofiban acetate	Integrin	Cardiovascular Disease
Orbofiban acetate is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.

SCH 38519	Bacterial	Infection
SCH 38519 is a **platelet aggregation** inhibitor. SCH 38519 inhibits thrombin-induced aggregation of human platelets with an IC₅₀ of 68 μg/mL. SCH 38519 is also active against Gram-positive and Gram-negative bacteria .

Trifenagrel	Others	Cardiovascular Disease
Trifenagrel is a platelet aggregation inhibitor that inhibits the inducing effects of arachidonic acid (AA) and collagen. The ED₅₀s of trifenagrel for inhibiting AA- and collagen-induced platelet aggregation in guinea pigs were 1.4 mg/kg and 9.4 mg/kg, respectively .

(±)-Clopidogrel hydrochloride	Others	Cardiovascular Disease
(±)-Clopidogrel hydrochloride is an antithrombotic agent that is ADP-selective and orally available. (±)-Clopidogrel hydrochloride inhibits platelet aggregation by inhibiting the binding of ADP to its platelet receptors .

4-Trifluoromethylsalicylic acid Desacetyl triflusal	Others	Others
4-Trifluoromethylsalicylic acid (Desacetyl triflusal) is a **platelet aggregation** inhibitor .

Prostaglandin I3 sodium	Others	Cardiovascular Disease
Prostaglandin I3 sodium is an inhibitor of platelet aggregation with vasodilatory effects .

Aglafoline 1 Publications Verification Aglafolin; Rocaglamide U; (-)-Methyl rocaglate	Others	Cardiovascular Disease
Aglafoline inhibits in a selective and concentration-dependent manner the aggregation and ATP release reaction induced in washed rabbit platelets by PAF (platelet-activating factor).

Anemarrhenasaponin I 2 Publications Verification	Others	Cardiovascular Disease
Anemarrhenasaponin I, a traditional Chinese medicine, shows remarkable inhibiting effect on platelet aggregation.

Plafibride ITA 104	Others	Cardiovascular Disease Metabolic Disease
Plafibride (ITA 104) is an orally active hypolipemic, platelet aggregation inhibitor .

Curcolone	Others	Cardiovascular Disease
Curcolone is a sesquiterpenoid that inhibits collagen-induced or arachidonic acid (AA)-induced platelet aggregation .

Hydrangetin 7-Hydroxy-8-methoxycoumarin	Others	Cardiovascular Disease
Hydrangetin inhibits platelet aggregation. Hydrangetin can be isolated from Zanthoxylum schinifolium .

Ticlopidine hydrochloride	Adenosine Receptor	Cardiovascular Disease
Ticlopidine hydrochloride is an adenosine diphosphate (ADP) receptor inhibitor against platelet aggregation with IC50 of ~2 μM.

Benzcyclane Bencyclane; Benzcyclan	Others	Cardiovascular Disease
Benzcyclane (Bencyclane; Benzcyclan) is a platelet aggregation inhibitor and a vasodilator effective in a variety of peripheral circulation disorders.

Prasugrel PCR 4099	P2Y Receptor	Cardiovascular Disease
Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

Prasugrel hydrochloride PCR 4099 hydrochloride	P2Y Receptor	Cardiovascular Disease
Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

Piperlotine D	Others	Cardiovascular Disease
Piperlotine D is an antiplatelet aggregation agent. Piperlotine D can be extracted from Piper lolot with antiplatelet aggregation activity. Piperlotine D inhibits arachidonic acid-induced platelet aggregation with an IC₅₀ of 43.4 μg/mL .

Spiradine F O-Acetylspiradine G; Spiradine G acetate
Spiradine F is a main alkaloidal component of spiraea japonioa L. fil. Spiradine F derivative can inhibit platelet-activating factor (PAF)-induced platelet aggregation .

YLF-466D 2 Publications Verification C24	AMPK	Cancer
YLF-466D is a newly developed AMPK activator, which inhibits platelet aggregation.

NQ301	Thrombin	Cardiovascular Disease
NQ301 is an antithrombotic agent; inhibits collagen-challenged rabbit platelet aggregation with an IC₅₀ of 10 mg/mL.

R-138727	P2Y Receptor	Cardiovascular Disease
R-138727, the thiol-containing active metabolite of Prasugrel, is an irreversible platelet P2Y12 receptor inhibitor. R-138727 inhibits ADP-induced platelet aggregation .

Hydroxylamine hydrochloride
Hydroxylamine hydrochloride is a selective monoamine oxidase (MAO) inhibitor used for inhibiting of platelet aggregation. Hydroxylamine hydrochloride is an intermediate of organic synthesis .

Prasugrel (Maleic acid) PCR 4099 (Maleic acid)	P2Y Receptor	Cardiovascular Disease
Prasugrel (PCR 4099) Maleic acid is a thienopyridine and proagent, inhibits platelet function. Prasugrel Maleic acid is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

MAHMA NONOate	Endogenous Metabolite NO Synthase	Cardiovascular Disease
MAHMA NONOate is a NO donor. MAHMA NONOate effectively inhibits platelet aggregation induced by either collagen or ADP .

GPVI antagonist 1	Glycoprotein VI	Cardiovascular Disease
GPVI antagonist 1 (compound 5) is a glycoprotein VI (GPVI) platelet receptor antagonist. GPVI antagonist 1 inhibits collagen-induced platelet aggregation with an IC₅₀ of 25.3 μM .

Indobufen Ibustrin	COX	Cardiovascular Disease
Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A₂ (TxA₂) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .

Carbacyclin Carbaprostacyclin; Carba-PGI2	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Carbacyclin is a PGI2 analogue, acts as a prostacyclin (PGI2) receptor agonist and vasodilator, and potently inhibits platelet aggregation.

Moscatin Plicatol B	Others	Cardiovascular Disease
Moscatin inhibits AA-induced platelet aggregation in a concentration-dependent manner with IC₅₀ values 37.2 μM .

Herquline A Herqueline A	Influenza Virus	Infection Cardiovascular Disease
Herquline A (Herqueline A) is a fungal piperazine alkaloid. Herquline A is a fungal metabolite that inhibits platelet aggregation and replication of the influenza virus .

Cyclomorusin Cyclomorusin A; Cyclomulberrochromene	Others	Cardiovascular Disease
Cyclomorusin (Cyclomorusin A; Cyclomulberrochromene) is a prenylflavonoid with antiplatelet activity. Cyclomorusin also inhibits markedly collagen-induced platelet aggregation .

Prostaglandin D3 PGD3	Prostaglandin Receptor	Cardiovascular Disease
Prostaglandin D3 (PGD3) is a prostaglandin that acts as an inhibitor of platelet aggregation and a modulator of autonomic neurotransmission in humans .

Epiyangambin	Platelet-activating Factor Receptor (PAFR)	Inflammation/Immunology Cancer
Epiyangambin is a competitive platelet activating factor receptor (PAF) antagonist that dose-dependently inhibits PAF-induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells) .

Cathepsin G	Cathepsin	Inflammation/Immunology
Cathepsin G acts as a potent agonist of human platelet activation leading to their aggregation., and can be used for screening of relevant inhibitors .

Batifiban TFA	Glycoprotein VI	Cardiovascular Disease
Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3 .

13,14-Dihydro PGE1 13,14-Dihydroprostaglandin E1	Endogenous Metabolite	Metabolic Disease
13,14-Dihydro PGE₁ is a metabolite of PGE₁ (Prostaglandin E1) which inhibits the ADP-induced platelet aggregation (ID₅₀ = 10.8 ng/mL platelet rich plasma) .

Jujuboside B	Others	Cardiovascular Disease
Jujuboside B is one of the major bioactive constituents isolated from Zizyphus jujuba. Jujuboside B can inhibit platelet aggregation .

N-Acetyldesloratadine SCH-37370	Platelet-activating Factor Receptor (PAFR) Histamine Receptor	Inflammation/Immunology
N-Acetyldesloratadine (SCH-37370) is a potent, orally active dual antagonist of platelet-activating factor (PAF) and histamine. N-Acetyldesloratadine inhibits PAF-induced aggregation of human platelets, with an IC₅₀ of 0.6 µM .

Trequinsin hydrochloride HL 725	Phosphodiesterase (PDE)	Metabolic Disease
Trequinsin hydrochloride (HL 725) is an extremely potent inhibitor of platelet CAMP phosphodiesterase (PDE), with an IC₅₀ of 0.25 nM. Trequinsin hydrochloride (HL 725) is an extremely potent inhibitor of the aggregation of human platelets induced in vitro by ADP, collagen, thrombin and epinephrine .

Satigrel E5510	Prostaglandin Receptor	Cardiovascular Disease
Satigrel (E5510) is a potent inhibitor of **platelet aggregation*. Satigrel inhibits* collagen- and arachidonic acid-induced platelet aggregation through preventing thromboxane A2 synthesis by selective inhibition of the target enzyme, PGHS1, which exists in platelets. Satigrel inhibits PGHS1 (IC₅₀: 0.081 μM) and PGHS2 (IC₅₀: 5.9 μM). Satigrel is against Type III PDE, Type V and Type II (IC₅₀: 15.7 μM, 39.8 μM and 62.4 μM, respectively) .

Cat. No.	Product Name	Type

HY-131384

8,11,14-Eicosatriynoic acid

8,11,14-Icosatriynoic acid

Biochemical Assay Reagents

8,11,14-Eicosatriynoic Acid, as an inhibitor of prostaglandin, leukotriene biosynthesis, and arachidonic acid-induced platelet aggregation, blocks human 12-lipoxygenase (12-LO), cyclooxygenase (COX)and 5-lipoxygenase (5-LO) with IC50 values of 0.46 μM, 14 μMand 25 μM, respectively. In addition, 8,11,14-Eicosatriynoic Acid inhibits the action of slow-reacting substances of allergic reactions, with IC50 value of 10 μM. Lipoxygenase is widely found in fungi, plants and animals. 12-LO involves in many important disease states and may play a role in oxidative glutamate toxicity. COX enzymes play complex roles in human physiology and pathology involving the neuronal, immune, renal, cardiovascular, gastrointestinal and reproductive systems. COX enzymes are blocked by aspirin and a variety of other NSAIDs, which makes them clinically important. 5-LO involves in cancer pathology. It is expressed by a variety of cancer cells, including colon, lung, breast, and prostate cancers, and promotes cancer cell growth and neovascularization . 8,11,14-Eicosatriynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name	Target	Research Area

HY-P1741

Fibrinogen-Binding Peptide 1 Publications Verification	Peptides	Cardiovascular Disease
Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .

HY-P1741A

Fibrinogen-Binding Peptide TFA 1 Publications Verification	Peptides	Cardiovascular Disease
Fibrinogen-Binding Peptide TFA (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide TFA binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .

HY-P4908

S-(1,2-Dicarboxyethyl)glutathione

Peptides Cardiovascular Disease

S-(1,2-Dicarboxyethyl)glutathione is a peptide that inhibits blood coagulation and platelet aggregation .
HY-P3052

RGDV

Peptides Cancer

RGDV is a platelet aggregation inhibitor. RGDV inhibits platelet-dependent thrombus formation. RGDV is used for tumor recognition via the targeting effect .
HY-P0314

Arg-Gly-Asp-Cys

Peptides Others

Arg-Gly-Asp-Cys is the binding motif of fibronectin to cell adhesion molecules, and can inhibit platelet aggregation and fibrinogen binding.

HY-P3012

Cathepsin G	Cathepsin	Inflammation/Immunology
Cathepsin G acts as a potent agonist of human platelet activation leading to their aggregation., and can be used for screening of relevant inhibitors .

HY-125053A

Batifiban TFA	Glycoprotein VI	Cardiovascular Disease
Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3 .

HY-P5991

K-Casein (106-116),bovine	Peptides	Cardiovascular Disease
K-Casein (106-116),bovine is a peptide that inhibits platelet aggregation and fibrinogen binding, plays an important role in atherosclerosis .

HY-125053

Batifiban	Integrin	Cardiovascular Disease
Batifiban, a cyclic peptide, is a platelet glycoprotein GPⅡb/Ⅲa antagonist, and inhibits platelet aggregation. Batifiban blocks circulating vitronectin binding to integrin ανβ3, Batifiban can be used for research of acute coronary syndromes .

HY-P0314A

Arg-Gly-Asp-Cys TFA	Peptides	Cardiovascular Disease
Arg-Gly-Asp-Cys TFA is the binding motif of fibronectin to cell adhesion molecules. Arg-Gly-Asp-Cys TFA can inhibit platelet aggregation and fibrinogen binding .

HY-P1189

Echistatin	Integrin	Metabolic Disease Inflammation/Immunology
Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of **platelet aggregation*. Echistatin is a potent inhibitor* of bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and α₅β₁ .

HY-P1189A

Echistatin TFA	Integrin	Metabolic Disease Inflammation/Immunology
Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of **platelet aggregation*. Echistatin is a potent inhibitor* of bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and α₅β₁ .

HY-P0012A

Aviptadil acetate 1 Publications Verification Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-P1263

tcY-NH2 (trans-Cinnamoyl)-YPGKF-NH2	Protease Activated Receptor (PAR)	Metabolic Disease Inflammation/Immunology
tcY-NH2 ((trans-Cinnamoyl)-YPGKF-NH2) is a potent selective PAR4 antagonist peptide. tcY-NH2 inhibits thrombin- and AY-NH₂-induced platelet aggregation and endostatin release, and can be used in the research of inflammation, immunology .

HY-P0012

Aviptadil 1 Publications Verification Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-P1263A

tcY-NH2 TFA 1 Publications Verification (trans-Cinnamoyl)-YPGKF-NH2 TFA	Protease Activated Receptor (PAR)	Metabolic Disease Inflammation/Immunology
tcY-NH2 ((trans-Cinnamoyl)-YPGKF-NH2) TFA is a potent selective PAR4 antagonist peptide. tcY-NH2 TFA inhibits thrombin- and AY-NH₂-induced platelet aggregation and endostatin release, and can be used in the research of inflammation, immunology .

HY-P5322

Thrombospondin (TSP-1)-derived CD36 binding motif	Peptides	Others
Thrombospondin (TSP-1)-derived CD36 binding motif is a biological active peptide. (This peptide is derived from thrombospondin and represents a binding motif responsible for thrombospondin-CD36 interaction. It is cyclized through a disulfide bond. Thrombospondin is a matrix-bound glycoprotein involved in cancer metastasis, tumor adhesion, and angiogenesis. This peptide has been shown to competitively inhibit platelet aggregation and tumor metastasis.)

Cat. No.	Product Name	Target	Research Area

HY-P99644

Glenzocimab ACT017	Inhibitory Antibodies	Cardiovascular Disease
Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke .

HY-P9934

Abciximab C7E3	Integrin	Cardiovascular Disease
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .

Cat. No.	Product Name	Chemical Structure

HY-15284S1

Prasugrel-d3
Prasugrel-d₃ is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].

HY-15284S

Prasugrel-d5
Prasugrel-d₅ is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].

HY-15284S2

Prasugrel-d4
Prasugrel-d₄ is the deuterium labeled Prasugrel[1]. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[2].

HY-W777681

Triflusal-13C6

Triflusal-13C6 is a C13-labeled Triflusal. Triflusal is a platelet aggregation inhibitor .

HY-B0153AS

Ticlopidine-d4 hydrochloride
Ticlopidine-d₄ (hydrochloride) is the deuterium labeled Ticlopidine hydrochloride. Ticlopidine hydrochloride is an adenosine diphosphate (ADP) receptor inhibitor against platelet aggregation with IC50 of ~2 μM.

HY-18763S

Indobufen-d5
Indobufen-d₅ is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes[1].

HY-W014632S

4-Trifluoromethylsalicylic acid-13C6
4-Trifluoromethylsalicylic acid- ¹³C₆ is the ¹³C labeled 4-Trifluoromethylsalicylic acid[1]. 4-Trifluoromethylsalicylic acid is a platelet aggregation inhibitor[2].

HY-Y0882S1

Hydroxylamine-d3 hydrochloride
Hydroxylamine-d₃ (hydrochloride) is the deuterium labeled Hydroxyamine hydrochloride[1]. Hydroxyamine hydrochloride is a selective monoamine oxidase (MAO) inhibitor used for inhibiting of platelet aggregation. Hydroxyamine hydrochloride is an intermediate of organic synthesis[2].

HY-B2158S

Chlorotrianisene-d9
Chlorotrianisene-d₉ is the deuterium labeled Chlorotrianisene. Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active estrogen receptor modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme COX-1 and inhibits platelet aggregation in whole blood[1][2][3].

HY-10163S1

Dabigatran-d3
Dabigatran-d₃ is the deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[1][2].

HY-10163S

Dabigatran-d4
Dabigatran-d₄ is deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[1][2].

HY-10163S2

Dabigatran-13C6
Dabigatran- ¹³C₆ is the ¹³C labeled Dabigatran[1]. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[2][3].

HY-10163S3

Dabigatran-13C,d3
Dabigatran- ¹³C,d₃ is the ¹³C- and deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[1][2].

HY-B0683S

Limaprost-d3
Limaprost-d₃ (17α,20-dimethyl-δ2-PGE1-d3) is the deuterium labeled Limaprost. Limaprost (OP1206) is a PGE1 analogue and a potent and orally active vasodilator. Limaprost increases blood flow and inhibits platelet aggregation. Limaprost pain relief, has antianginal effects, and can be used for ischaemic symptoms research[1][2].

HY-17459S

Clopidogrel-d3 hydrogen sulfate

Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].

HY-B0131S

Prostaglandin E1-d4

Prostaglandin E1-d₄ is the deuterium labeled Prostaglandin E1. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases[1][2][3].

HY-W010918S

Adenosine 5'-diphosphate-d13 dilithium

Adenosine 5'-diphosphate-d₁₃ (Adenosine diphosphate-d₁₃ dilithium; ADP-d₁₃) dilithium is deuterium labeled Adenosine 5'-diphosphate (HY-W010918). Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P_2T-purinoceptors.

HY-W010918S1

Adenosine 5'-diphosphate-13C10 dilithium

Adenosine 5'-diphosphate- ¹³C₁₀ (Adenosine diphosphate- ¹³C₁₀ dilithium; ADP- ¹³C₁₀) dilithium is ¹³C-labeled Adenosine 5'-diphosphate (HY-W010918). Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P_2T-purinoceptors.

HY-W010918S2

Adenosine 5'-diphosphate-15N5 dilithium

Adenosine 5'-diphosphate- ¹⁵N₅ (Adenosine diphosphate- ¹⁵N₅ dilithium; ADP- ¹⁵N₅) dilithium is ¹⁵N labeled Adenosine 5'-diphosphate (HY-W010918). Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P_2T-purinoceptors.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

inhibits platelet aggregation

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products